Exceptional Expansion Across Specialized Therapeutic Portfolios
Galderma's financial disclosures for the nine-month period delivered substantial optimism across Swiss capital markets as third-quarter sales accelerated by 26%, lifting total revenues from January to September to 4.77 billion dollars. The primary growth engine behind this milestone was the therapeutic dermatology division, which posted a remarkable 64.4% surge in revenue, catalyzed by aggressive clinical adoption and patient demand for its newly launched dermatological treatment Nemluvio.
Complementing this prescription success, the enterprise's foundational consumer and aesthetic pillars exhibited sustained vitality, with dermatological skincare revenues climbing 16.2% and injectable aesthetics advancing 13.2%.

















